Technical Analysis for BYSI - BeyondSpring, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 1 day ago |
Down 2 % | 1 day ago |
Possible NR7 | 1 day ago |
Down 1% | 1 day ago |
Possible NR7 | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.0 |
52 Week Low | 0.7777 |
Average Volume | 23,936 |
200-Day Moving Average | 2.25 |
50-Day Moving Average | 2.15 |
20-Day Moving Average | 1.94 |
10-Day Moving Average | 1.77 |
Average True Range | 0.16 |
RSI (14) | 34.64 |
ADX | 36.21 |
+DI | 7.16 |
-DI | 22.44 |
Chandelier Exit (Long, 3 ATRs) | 1.86 |
Chandelier Exit (Short, 3 ATRs) | 1.97 |
Upper Bollinger Bands | 2.35 |
Lower Bollinger Band | 1.53 |
Percent B (%b) | 0.26 |
BandWidth | 41.99 |
MACD Line | -0.14 |
MACD Signal Line | -0.12 |
MACD Histogram | -0.0157 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.83 | ||||
Resistance 3 (R3) | 1.82 | 1.78 | 1.81 | ||
Resistance 2 (R2) | 1.78 | 1.76 | 1.79 | 1.81 | |
Resistance 1 (R1) | 1.76 | 1.75 | 1.77 | 1.77 | 1.80 |
Pivot Point | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 |
Support 1 (S1) | 1.70 | 1.70 | 1.72 | 1.71 | 1.68 |
Support 2 (S2) | 1.67 | 1.69 | 1.67 | 1.67 | |
Support 3 (S3) | 1.65 | 1.67 | 1.67 | ||
Support 4 (S4) | 1.65 |